發(fā)布時間：2018-09-14 19:00

【摘要】：目的:通過觀察標準化塵螨變應(yīng)原制劑治療變應(yīng)性鼻炎(AR)的不良反應(yīng),評價特異性免疫治療的安全性。方法:使用安脫達標準化塵螨變應(yīng)原制劑皮下注射治療386例AR患者,觀察其不良反應(yīng)發(fā)生情況并計算不良反應(yīng)發(fā)生率。結(jié)果:386例AR患者較明顯的不良反應(yīng)發(fā)生率為10.9%(42/386),其中大的局部不良反應(yīng)發(fā)生率為2.6%(10/386),全身不良反應(yīng)發(fā)生率為9.3%(36/386),其中輕度全身反應(yīng)(1級)34例,中度全身反應(yīng)(2級)1例,嚴重(非致命)全身反應(yīng)(3級)1例,無一例患者發(fā)生過敏性休克(4級);3種治療方案不良反應(yīng)的發(fā)生率以常規(guī)方案最高(21.1%),成人集群方案居次(11.9%),兒童集群方案最低(1.5%);不良反應(yīng)大多發(fā)生在劑量遞增階段中后期及維持治療階段早期。結(jié)論:對AR患者進行規(guī)范的特異性免疫治療是一種安全有效的對因治療方法,嚴格掌握治療流程并執(zhí)行操作規(guī)范,同時采取針對性措施可減少不良反應(yīng)的發(fā)生。
[Abstract]:Objective: to evaluate the safety of specific immunotherapy by observing the adverse reactions of standardized dust mite allergen in the treatment of allergic rhinitis (AR). Methods: 386 patients with AR were treated by subcutaneous injection of Amida standardized dust mite allergen. The adverse reactions were observed and the incidence rate of adverse reactions was calculated. Results the incidence of adverse reactions was 10.9% (42 / 386) in patients with AR. The incidence of major local adverse reactions was 2.6% (10 / 386), and the incidence of systemic adverse reactions was 9.3% (36 / 386). There were 34 cases of mild systemic reactions (grade 1) and 1 case of moderate systemic reactions (grade 2). Severe (non-fatal) systemic reaction (grade 3), No patient with anaphylactic shock (grade 4) had the highest incidence of adverse reactions (21.1%), adult cluster (11.9%) and children (1.5%) had the highest incidence of adverse reactions, and most of the adverse reactions occurred in the dose-increasing phase. Late stage and early stage of maintenance therapy. Conclusion: the standard specific immunotherapy for AR patients is a safe and effective method to treat the cause, strictly master the treatment process and carry out the operation standard, and take targeted measures to reduce the occurrence of adverse reactions.
【作者單位】： 南昌大學(xué)第一附屬醫(yī)院耳鼻咽喉-頭頸外科;
【分類號】：R765.21

【參考文獻】

相關(guān)期刊論文 前8條

1 韓虹;陳少華;邱前輝;;安脫達塵螨疫苗治療變應(yīng)性鼻炎的療效及安全性評價[J];廣東醫(yī)學(xué);2007年06期

2 符徵;蔡飛;孫亮;王剛;黎青;林霞;鄧慧林;王榮夙;;安脫達標準疫苗免疫治療的安全性[J];臨床耳鼻咽喉頭頸外科雜志;2009年18期

3 劉軍;萬靜;周意;劉忠;;安脫達標準化塵螨疫苗治療變應(yīng)性鼻炎的療效和安全性評價[J];臨床耳鼻咽喉頭頸外科雜志;2012年11期

4 孫臻峰;孟晴紅;張佳;孫雅靜;董頻;;標準化塵螨變應(yīng)原疫苗治療過敏性鼻炎的不良反應(yīng)分析[J];中國臨床藥學(xué)雜志;2009年06期

5 王成碩,張羅,韓德民;標準化塵螨變應(yīng)原疫苗治療變應(yīng)性鼻炎的療效和安全性評估[J];首都醫(yī)科大學(xué)學(xué)報;2005年03期

6 易華容;劉遠華;葉菁;;塵螨變應(yīng)原疫苗治療變應(yīng)性鼻炎的早期療效觀察[J];臨床合理用藥雜志;2013年11期

7 曾雪妮;李靖;鮮墨;黃夏飛;潘瑤;符始艷;;皮下注射標準化屋塵螨變應(yīng)原疫苗治療支氣管哮喘和(或)變應(yīng)性鼻炎的速發(fā)不良反應(yīng)[J];中華臨床免疫和變態(tài)反應(yīng)雜志;2013年04期

8 陳莉娜;劉瀚e，

本文編號：2243600